Please assess the completion status of the following clinical trial:

Trial Title: MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed persistent or recurrent stage II to IV high grade serous epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Disease can be platinum-sensitive or platinum-resistant.~2. Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible.~3. Confirmation of tumor aFR expression (≥70% of tumor cells with ≥2+ aFR staining).~4. Subjects must have measureable disease as defined by RECIST 1.1 criteria.~5. Patients with asymptomatic CNS metastases that have been treated and are off steroids are allowed. They must meet the following at the time of eligibility confirmation by physician-investigator:~   1. No concurrent treatment for the CNS disease~  2. No progression of CNS metastasis on brain MRI at screening~  3. No evidence of leptomeningeal disease or cord compression~6. Patients ≥ 18 years of age.~7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~8. Satisfactory organ and bone marrow function as defined by the following:~   i. Absolute neutrophil count ≥ 1,000/μl ii. Platelets ≥75,000/μl iii. Hemoglobin ≥ 9 g/dL iv. Total bilirubin ≤ 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor v. Creatinine ≤ 1.5x the institutional normal upper limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5x the institutional normal upper limit viii. Cardiac ejection fraction of ≥40%~9. Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤ 1.5 and a PTT ≤ 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters.~10. Provides written informed consent.~11. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3.~Exclusion Criteria:~1. High grade serous ovarian, fallopian, or primary peritoneal cancer that is platinum refractory, defined as disease that has clinical or radiographic progression on platinum-based chemotherapy, as per the discretion of the treating physician.~2. Patients with symptomatic CNS metastases are excluded.~3. Participation in a therapeutic investigational study within 4 weeks prior to eligibility confirmation by physician-investigator, or anticipated treatment with another investigational product while on study. This refers to non-commercially approved investigational drugs different than those used in this protocol.~4. Active invasive cancer other than ovarian cancers. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder cancer) are not excluded.~5. HIV infection~6. Hepatitis B or hepatitis C infection~7. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to \>/= 10 mg of prednisone. Patients with autoimmune neurologic diseases (such as multiple sclerosis) will be excluded.~8. Patients with active and uncontrolled infection.~9. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (\<10 mg daily equivalent of prednisone). Corticosteroids treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy administration is allowed per institutional guidance. The use of topical and/or inhaled steroids are not exclusionary.~10. Patients requiring supplemental oxygen therapy.~11. Prior therapy with lentiviral gene modified cells.~12. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).~13. Any ascites requiring therapeutic drainage within 4 weeks prior to eligibility confirmation by physician-investigator.~14. Pregnant or breastfeeding women.~15. Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results, and, in the opinion of the physician-investigator, would make the patient inappropriate for entry into the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: MOv19-BBz CAR T cells without chemo (Type: EXPERIMENTAL): Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
- Cohort 2: MOv19-BBz CAR T cells after chemo (Type: EXPERIMENTAL): Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
- Cohort 3: MOv19-BBz CAR T cells after chemo (Type: EXPERIMENTAL): Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
- Cohort-1: without chemo;only if dose de-escalation required (Type: EXPERIMENTAL): Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.

Based on this trial design, predict the completion outcome and termination type (if applicable).